Syros Pharmaceuticals, Inc. - נכסים נקיים למניה בודדת SYRS
The final book value per share demonstrates capital resilience, where -0.41 shows the current value of the metric. The business dynamics of Syros Pharmaceuticals (SYRS) depend on the phases of clinical trials in oncology, remaining independent of market cycles. The humanitarian status of its developments minimizes geopolitical risks and external sanctions. High profitability is ensured by diversified bio-raw material logistics and a reliable pool of laboratory contractors.
syros.com - פילוחים אנליטיים ומדדי מפתח (SYRS)
Book value per share reflects the portion of equity attributable to a single security after deducting all liabilities, serving as an indicator of the business's intrinsic value. By analyzing the book value per share chart, an investor can see the capital management efficiency of Syros Pharmaceuticals (SYRS), which is optimized by outsourcing production and testing to third-party contractors to concentrate resources on genomic research.